Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Rivaroxaban
Drug ID BADD_D01954
Description Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. FDA approved on July 1, 2011.
Indications and Usage Not Available
Marketing Status Prescription
ATC Code B01AF01
DrugBank ID DB06228
KEGG ID D07086
MeSH ID D000069552
PubChem ID 9875401
TTD Drug ID D0KG3R
NDC Product Code 50090-3625; 50458-579; 50458-575; 65015-898; 58032-2029; 55154-1424; 53296-0109; 14799-2023; 55111-966; 76072-1008; 47848-039; 55154-1423; 14501-0079; 65727-050; 52286-0025; 59285-009; 65862-971; 16436-0109; 75945-050; 50090-4468; 53104-7730; 50090-3639; 53747-068; 66022-0203; 50090-4469; 50458-580; 64220-176; 63415-0523; 64552-4049; 50458-578; 46708-899; 82513-0001; 66174-0087; 72969-109; 66039-913; 50458-584; 65372-1193; 50458-577; 55154-1422; 69218-0500
Synonyms Rivaroxaban | 5-chloro-N-(((5S)-2-oxo-3-(4-(3-oxomorpholin-4-yl)phenyl)-1,3-oxazolidin-5-yl)methyl)thiophene-2-carboxamide | Xarelto | BAY 59-7939 | BAY 59 7939 | BAY 597939
Chemical Information
Molecular Formula C19H18ClN3O5S
CAS Registry Number 366789-02-8
SMILES C1COCC(=O)N1C2=CC=C(C=C2)N3CC(OC3=O)CNC(=O)C4=CC=C(S4)Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Atrioventricular block02.03.01.002--Not Available
Atrioventricular block complete02.03.01.003--
Atypical pneumonia22.07.01.010; 11.01.09.012--Not Available
Autoimmune hepatitis10.04.09.001; 09.01.07.019--Not Available
Azotaemia20.01.01.001--Not Available
B-cell lymphoma01.15.01.001; 16.28.01.001--Not Available
Back pain15.03.04.005--
Bacteraemia11.01.11.001--
Barrett's oesophagus07.11.03.0020.000714%Not Available
Basal cell carcinoma23.08.02.001; 16.03.02.001--Not Available
Benign prostatic hyperplasia21.04.02.0010.001071%Not Available
Bile duct cancer16.07.01.001; 09.04.02.0010.000140%Not Available
Bile duct stone09.02.02.003--Not Available
Bilirubin conjugated increased13.03.01.007--Not Available
Biopsy breast13.20.02.0040.000357%Not Available
Bladder cancer16.08.01.001; 20.03.04.001--Not Available
Bladder neoplasm20.03.04.002; 16.08.03.0020.002499%Not Available
Bleeding time prolonged13.01.02.0020.001249%Not Available
Blindness17.17.01.003; 06.02.02.001--Not Available
Blindness transient17.17.01.004; 06.02.02.002--Not Available
Blindness unilateral17.17.01.016; 06.02.02.0090.003391%Not Available
Blister23.03.01.001; 12.01.06.002--Not Available
Blood albumin decreased13.09.01.001--Not Available
Blood bilirubin increased13.03.01.008--
Blood calcium increased13.11.01.003--Not Available
Blood chloride decreased13.11.01.004--Not Available
Blood cholesterol increased13.12.01.002--
Blood creatine increased13.13.01.0010.001428%Not Available
Blood creatine phosphokinase increased13.04.01.001--
Blood creatine phosphokinase MB increased13.04.01.0060.000357%Not Available
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 56 Pages